Biodesix Announces AACR 2026 Posters and Presentations, Highlighting Novel Diagnostic Test Discovery & Pipeline Development
MWN-AI** Summary
Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company based in Louisville, Colorado, has announced its participation in the upcoming American Association for Cancer Research (AACR) Annual Meeting to be held in San Diego from April 17-22, 2026. The company will unveil seven abstracts, which include two oral presentations, showcasing its innovative capabilities in both blood- and tissue-based diagnostic testing and monitoring across various applications.
The presentations at AACR will highlight Biodesix's extensive expertise in test discovery and development, underscored by over a decade of experience in supporting clinical development and commercialization of diagnostics and therapeutics. CEO Scott Hutton emphasized the potential clinical impact of Biodesix's genomic and proteomic technologies, paired with advanced data informatics, in driving momentum for its Development Services business as they enter 2026.
Key highlights from the conference include the introduction of a new clinical myeloid panel validated on the Thermo Fisher Ion Torrent Genexus System, capable of delivering sequencing results within 24 hours. Additionally, a real-world analysis of variant-level frequencies from liquid biopsy testing in Non-Small Cell Lung Cancer (NSCLC) will feature prominently during the conference.
Furthermore, Biodesix will showcase a novel multi-omic approach for monitoring molecular residual disease (MRD) alongside collaborations with renowned institutions like Thermo Fisher Scientific and Memorial Sloan Kettering Cancer Center. These presentations are set to advance understanding in areas such as ultra-sensitive biomarker detection and the integration of proteomic and genomic workflows.
Biodesix continues to establish its leadership in the diagnostic landscape, emphasizing its commitment to enhancing clinical care and improving outcomes for patients, particularly in the realm of lung disease. For more information on Biodesix and its portfolio of diagnostic tests, visit biodesix.com.
MWN-AI** Analysis
Biodesix, Inc. (Nasdaq: BDSX) is set to gain significant attention at the upcoming American Association for Cancer Research (AACR) Annual Meeting with the presentation of seven abstracts, including two oral sessions. This event underscores Biodesix's solid footing in the diagnostics sector, particularly in oncology. Investors should closely monitor these developments as they may impact BDSX's market performance.
The company's focus on innovative blood- and tissue-based testing technologies, particularly in liquid biopsy applications for non-small cell lung cancer (NSCLC), positions it well within a rapidly advancing market. The introduction of their new molecular residual disease (MRD) pipeline, featuring advanced genomic and proteomic technologies, points to Biodesix's commitment to expanding its diagnostic capabilities, which could lead to increased market penetration and revenue streams.
Moreover, the validation of a next-generation sequencing myeloid panel and partnerships with prominent organizations like Thermo Fisher Scientific suggest strong collaborative potential, enhancing Biodesix's credibility and technical depth in clinical diagnostics. These partnerships can accelerate product development and commercialization, potentially leading to higher market share.
Given the robust data presented at AACR, investors should consider Biodesix as a candidate for both growth and strategic investment, particularly with its focus on personalized medicine and integration of advanced informatics in diagnostics. The market for cancer diagnostics is poised for substantial growth, and Biodesix's innovative approaches could yield significant returns.
However, as with any investment in biotechnology, potential investors should remain aware of inherent risks including regulatory hurdles and market competition. It would be prudent to keep abreast of the outcomes from the AACR presentations and subsequent market reactions to gauge Biodesix's trajectory moving forward. Overall, BDSX presents a promising proposition for investors looking to capitalize on advancements in diagnostic technologies within oncology.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LOUISVILLE, Colo., April 06, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that the company will present seven abstracts, including two oral sessions, at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, from April 17 - 22, 2026. The presentations demonstrate Biodesix capabilities in blood- and tissue-based testing and monitoring across a range of applications.
“Biodesix expertise in test discovery and development, regulatory, reimbursement, and commercialization provides an exceptional level of service for our partners across a range of applications. The AACR presentations showcase basic research through clinical applications and pre-validated assays available for biopharma and life science partners, as well as advancements in our pipeline efforts. The data are reinforced by more than a decade of experience supporting the clinical development and commercialization of new diagnostics and therapeutics,” said Gary Pestano, PhD, Chief Scientific Officer, Biodesix.
“The depth of experience and success across the Biodesix team, spanning real-world clinical care and cutting-edge research, will be on full display at this year’s AACR. It is especially exciting to see our genomic and proteomic technologies, combined with advanced data informatics, translating into meaningful clinical impact in our pipeline product concepts while also fueling strong momentum in our Development Services business as we move into 2026,” said Scott Hutton, CEO, Biodesix.
Tumor & Immune Profiling Expertise
Biodesix oral and poster presentations highlight diverse technology platforms, rapid turn-around times for our clinical tests, and extensive capabilities in immune and tumor profiling using mass spectrometry, Bio-Rad Droplet Digital PCR™, and Thermo Fisher Ion AmpliSeq™ platforms. In addition, Biodesix has validated a new clinical myeloid panel on the Thermo Fisher Ion Torrent™ Genexus™ System. The platform supports an automated clinical next-generation sequencing (NGS) workflow and can deliver sequencing results in as little as 24 hours.
Sunday, April 19 | 3PM–5PM PST? | Oral Presentation | Room 17, Mezzanine Level, Convention Center
?Title: Real-world analysis of NSCLC* variant-level frequencies from liquid biopsy testing in diverse U.S. populations?
Monday, April 20 | 2PM–5PM PST | Poster Section 41
Poster: 3743. ddPLEX EGFR/KRAS/BRAF: A highly multiplexed droplet digital PCR™ (ddPCR™) panel for ultra-sensitive NSCLC biomarker detection
Wednesday, April 22 | 9AM–12PM PST? | Poster Section 39?
Poster: Blood-based proteomic profiling reveals novel biomarkers of Neuroendocrine Prostate Cancer?
Monday, April 20 | 2PM–5PM PST? | Poster Section 44?
Title: Performance validation of a next generation sequencing myeloid assay on an integrated nucleic acid purification and sequencing system?
Molecular Residual Disease (MRD) Product Pipeline
Another set of presentations highlights a novel, multi-omic approach to MRD monitoring. Thermo Fisher Scientific, Bio-Rad Laboratories, and Memorial Sloan Kettering Cancer Center will co-present new data on proteomic and genomic biomarkers as well as bioinformatics workflows central to the Biodesix MRD pipeline tests.
Monday, April 20 | 12:30PM | Spotlight Theater B - Sails Pavilion - Conv Ctr
Title: Leveraging Droplet Digital PCR™* (ddPCR™) for MRD Detection and Monitoring in Solid Tumors and Heme Malignancies
Tuesday, April 21 | 2PM–5PM PST? | Poster Section 1?
Poster: 5437. Sensitive detection of rare cfDNA variants utilizing molecular technologies and a novel informatics platform: A combined genomic and proteomic MRD application.?
?Wednesday, April 22 | 9AM–12PM PST? | Poster Section 45?
Poster: 7828. Development of a comprehensive tumor-informed ctDNA workflow for ultrasensitive molecular residual disease (MRD) detection using diverse tumor profiling inputs?
The full abstracts for Biodesix and a list of all abstracts being presented at the AACR Annual Meeting can be found here.
- ddPCR™ technology is a trademark of Bio-Rad Laboratories, Inc.
- Ion Torrent™ Genexus® System and Ion AmpliSeq™ Platform are trademarks of Thermo Fisher Scientific.
- NSCLC is the acronym for Non-Small Cell Lung Cancer.
About Biodesix:
Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.
Biodesix Contacts:
Media:
Natalie St. Denis, Director Corporate Communications
natalie.stdenis@biodesix.com
(720) 925-9285
Investors:
Chris Brinzey, Partner, ICR
chris.brinzey@icrhealthcare.com
(339) 970-2843
FAQ**
How do the recent presentations by Biodesix Inc. BDSX at the AACR Annual Meeting reflect their advancements in blood- and tissue-based testing and monitoring capabilities?
Can you elaborate on the significance of the multi-omic approach to MRD monitoring presented by Biodesix Inc. BDSX in collaboration with partner institutions?
What potential market impact could the validated myeloid panel on the Thermo Fisher Ion Torrent Genexus System have for Biodesix Inc. BDSX in the realm of cancer diagnostics?
How does Biodesix Inc. BDSX plan to leverage its expertise in genomic and proteomic technologies to enhance clinical outcomes and drive growth in the upcoming years?
**MWN-AI FAQ is based on asking OpenAI questions about Biodesix Inc. (NASDAQ: BDSX).
NASDAQ: BDSX
BDSX Trading
-5.4% G/L:
$15.62 Last:
8,528 Volume:
$16.28 Open:
